Pipeline
| Phase 1 | Phase 2 | Phase 3 | NDA/MAA Filing | Approved | Milestones | |
|---|---|---|---|---|---|---|
| ZTlido® (lidocaine topical system) 1.8% (Post-herpetic Neuralgia-PHN, Shingles pain) |
|
Launched October 2018 | ||||
| SP-102 (Lumbar Radicular/Sciatica Pain) |
|
Phase 3 trial enrollment completed in 2H 2021 | ||||
| SP-103 Lidocaine Topical System 5.4% (3X)(Acute Low Back Pain) |
|
Initiating Phase 2 in 2H 2021 | ||||
| SP-104 Delayed Burst Release Low Dose Naltrexone (Fibromyalgia) |
|
Initiating Phase 1 in 2H 2021 | ||||
| Drug | Indication | Stage | ZTlido® (lidocaine topical system) 1.8% | (Post-herpetic Neuralgia-PHN, Shingles pain) | Approved |
|---|---|---|
| SP-102 | (Lumbar Radicular/Sciatica Pain) | Phase 3 |
| SP-103 | Lidocaine Topical System 5.4% (3X)(Acute Low Back Pain) | Phase 2 |
| SP-104 | Delayed Burst Release Low Dose Naltrexone (Fibromyalgia) | Phase 1 |